316 related articles for article (PubMed ID: 31127350)
21. ¹⁸F-FDG PET metabolic parameters and MRI perfusion and diffusion parameters in hepatocellular carcinoma: a preliminary study.
Ahn SJ; Park MS; Kim KA; Park JY; Kim I; Kang WJ; Lee SK; Kim MJ
PLoS One; 2013; 8(8):e71571. PubMed ID: 23940769
[TBL] [Abstract][Full Text] [Related]
22. Early prediction of triple negative breast cancer response to cisplatin treatment using diffusion-weighted MRI and
Nguyen-Thu H; Hanaoka H; Nakajima T; Yamaguchi A; Nguyen-Cong T; Kartamihardja AAP; Tsushima Y
Breast Cancer; 2018 May; 25(3):334-342. PubMed ID: 29357023
[TBL] [Abstract][Full Text] [Related]
23. Anatomical and functional volume concordance between FDG PET, and T2 and diffusion-weighted MRI for cervical cancer: a hybrid PET/MR study.
Sun H; Xin J; Zhang S; Guo Q; Lu Y; Zhai W; Zhao L; Peng W; Wang B
Eur J Nucl Med Mol Imaging; 2014 May; 41(5):898-905. PubMed ID: 24463908
[TBL] [Abstract][Full Text] [Related]
24. Validation of preclinical multiparametric imaging for prediction of necrosis in hepatocellular carcinoma after embolization.
Braren R; Altomonte J; Settles M; Neff F; Esposito I; Ebert O; Schwaiger M; Rummeny E; Steingoetter A
J Hepatol; 2011 Nov; 55(5):1034-40. PubMed ID: 21354233
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the [
Brasse D; Burckel H; Marchand P; Rousseau M; Ouadi A; Vanstalle M; Finck C; Laquerriere P; Boisson F
Mol Imaging Biol; 2021 Oct; 23(5):724-732. PubMed ID: 33847900
[TBL] [Abstract][Full Text] [Related]
26. The Synergistic Effect of Selumetinib/Docetaxel Combination Therapy Monitored by [(18)F]FDG/[(18)F]FLT PET and Diffusion-Weighted Magnetic Resonance Imaging in a Colorectal Tumor Xenograft Model.
Honndorf VS; Schmidt H; Wiehr S; Wehrl HF; Quintanilla-Martinez L; Stahlschmidt A; Barjat H; Emmas SA; Pichler BJ
Mol Imaging Biol; 2016 Apr; 18(2):249-57. PubMed ID: 26276154
[TBL] [Abstract][Full Text] [Related]
27. [Diagnostic accuracy of 18F-FDG positron emission tomography for evaluation of hepatocellular carcinoma].
Shin JA; Park JW; An M; Choi JI; Kim SH; Kim SK; Lee WJ; Park SJ; Hong EK; Kim CM
Korean J Hepatol; 2006 Dec; 12(4):546-52. PubMed ID: 17237633
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Iodine-125 Interstitial Brachytherapy Using Micro-Positron Emission Tomography/Computed Tomography with 18F-Fluorodeoxyglucose in Hepatocellular Carcinoma HepG2 Xenografts.
Zhu Y; Dong M; Yang J; Zhang J
Med Sci Monit; 2019 Jan; 25():371-380. PubMed ID: 30636171
[TBL] [Abstract][Full Text] [Related]
29. The Role of 18F-FDG PET/MRI in the Assessment of Primary Intrahepatic Neoplasms.
Çelebi F; Yaghouti K; Cindil E; Dogusoy GB; Tokat Y; Balcı C
Acad Radiol; 2021 Feb; 28(2):189-198. PubMed ID: 32111468
[TBL] [Abstract][Full Text] [Related]
30. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic and prognostic value of pretreatment SUV in 18F-FDG/PET in breast cancer: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging.
Baba S; Isoda T; Maruoka Y; Kitamura Y; Sasaki M; Yoshida T; Honda H
J Nucl Med; 2014 May; 55(5):736-42. PubMed ID: 24665089
[TBL] [Abstract][Full Text] [Related]
32. Identification of Keratin 19-Positive Cancer Stem Cells Associating Human Hepatocellular Carcinoma Using
Kawai T; Yasuchika K; Seo S; Higashi T; Ishii T; Miyauchi Y; Kojima H; Yamaoka R; Katayama H; Yoshitoshi EY; Ogiso S; Kita S; Yasuda K; Fukumitsu K; Nakamoto Y; Hatano E; Uemoto S
Clin Cancer Res; 2017 Mar; 23(6):1450-1460. PubMed ID: 27663597
[No Abstract] [Full Text] [Related]
33. Diagnostic value of combining ¹¹C-choline and ¹⁸F-FDG PET/CT in hepatocellular carcinoma.
Castilla-Lièvre MA; Franco D; Gervais P; Kuhnast B; Agostini H; Marthey L; Désarnaud S; Helal BO
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):852-859. PubMed ID: 26577938
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of metabolic characteristics and viability of lipiodolized hepatocellular carcinomas using 18F-FDG PET/CT.
Kim HO; Kim JS; Shin YM; Ryu JS; Lee YS; Lee SG
J Nucl Med; 2010 Dec; 51(12):1849-56. PubMed ID: 21098794
[TBL] [Abstract][Full Text] [Related]
35. Early dynamic 18F-FDG PET to detect hyperperfusion in hepatocellular carcinoma liver lesions.
Schierz JH; Opfermann T; Steenbeck J; Lopatta E; Settmacher U; Stallmach A; Marlowe RJ; Freesmeyer M
J Nucl Med; 2013 Jun; 54(6):848-54. PubMed ID: 23528383
[TBL] [Abstract][Full Text] [Related]
36. Use of (18)F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization.
Kim MJ; Kim YS; Cho YH; Jang HY; Song JY; Lee SH; Jeong SW; Kim SG; Jang JY; Kim HS; Kim BS; Lee WH; Park JM; Lee JM; Lee MH; Choi DL
Korean J Intern Med; 2015 May; 30(3):308-15. PubMed ID: 25995661
[TBL] [Abstract][Full Text] [Related]
37. Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation.
Lin CY; Liao CW; Chu LY; Yen KY; Jeng LB; Hsu CN; Lin CL; Kao CH
Clin Nucl Med; 2017 Apr; 42(4):e183-e187. PubMed ID: 28114226
[TBL] [Abstract][Full Text] [Related]
38. Prediction of clinical outcome after stereotactic body radiotherapy for non-small cell lung cancer using diffusion-weighted MRI and (18)F-FDG PET.
Iizuka Y; Matsuo Y; Umeoka S; Nakamoto Y; Ueki N; Mizowaki T; Togashi K; Hiraoka M
Eur J Radiol; 2014 Nov; 83(11):2087-92. PubMed ID: 25174774
[TBL] [Abstract][Full Text] [Related]
39. Combined DCE-MRI- and FDG-PET enable histopathological grading prediction in a rat model of hepatocellular carcinoma.
Kaissis GA; Lohöfer FK; Hörl M; Heid I; Steiger K; Munoz-Alvarez KA; Schwaiger M; Rummeny EJ; Weichert W; Paprottka P; Braren R
Eur J Radiol; 2020 Mar; 124():108848. PubMed ID: 32006931
[TBL] [Abstract][Full Text] [Related]
40. (4S)-4-(3-18F-fluoropropyl)-L-glutamate for imaging of xC transporter activity in hepatocellular carcinoma using PET: preclinical and exploratory clinical studies.
Baek S; Mueller A; Lim YS; Lee HC; Lee YJ; Gong G; Kim JS; Ryu JS; Oh SJ; Lee SJ; Bacher-Stier C; Fels L; Koglin N; Schatz CA; Dinkelborg LM; Moon DH
J Nucl Med; 2013 Jan; 54(1):117-23. PubMed ID: 23232273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
